1. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma 
Alexander Kreuter, MD, Julia Hyun, MD, Markus Stücker, MD, Anna Sommer, MD, Peter Altmeyer, MD, Thilo Gambichler, MD 
Journal of the American Academy of Dermatology 
Volume 54, Issue 3, Pages (March 2006)
DOI: /j.jaad
Copyright © 2006 American Academy of Dermatology, Inc. Terms and Conditions

2. Fig 1
Flow diagram. ITT population, All randomized patients who performed UV therapy and from whom at least one postbaseline MSS was available; LD, low dose; MD, medium dose; NB, narrowband; safety population, all patients who had at least applied one cycle of UV therapy; withdrawn, patients who were lost to follow-up, or discontinued study because of unsatisfactory outcome or other reasons.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad )
Copyright © 2006 American Academy of Dermatology, Inc. Terms and Conditions

3. Fig 2
A, Clinical presentation of patient with active morphea before treatment with low-dose UVA1. B, Complete clearance of all signs of active disease. Residual postinflammatory hyperpigmentation.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad )
Copyright © 2006 American Academy of Dermatology, Inc. Terms and Conditions

4. Fig 3
A, Localized scleroderma treated with narrowband (NB) UVB: pretreatment clinical aspects. B, Remarkable improvement after NB UVB phototherapy.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad )
Copyright © 2006 American Academy of Dermatology, Inc. Terms and Conditions

5. Fig 4
A, Pretreatment biopsy specimen of patient receiving medium-dose (MD) UVA1. B, Posttreatment biopsy specimen: normalization of skin architecture after MD UVA1. (A and B, Hematoxylin-eosin stain; original magnifications: ×40.)
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad )
Copyright © 2006 American Academy of Dermatology, Inc. Terms and Conditions